Posted by Michael Wonder on 07 Dec 2018
NICE OKs NHS funding for Gilead’s CAR T-cell therapy
7 December 2018 - Gilead’s CAR T-cell therapy Yescarta will be available on the NHS to some adults with lymphoma.
The National Institute for Health and Care Excellence says the treatment can be funded via the Cancer Drugs Fund for adults with relapsed or refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma, two aggressive subtypes of non-Hodgkin lymphoma.
Yescarta (axicabtagene ciloleucel) will be offered to people whose disease has not responded after two or more rounds of chemotherapy or relapsed after a stem cell transplant.
